The Board of Gavi, the Vaccine Alliance announced a series of decisions that provide a framework for an acceleration of global immunisation – including approval of "Gavi 6.0", the Alliance's 2026-2030 strategy, expansion of Gavi's vaccine portfolio, and plans to support global health security and regional manufacturing through the African Vaccine Manufacturing Accelerator and a First Response Fund for use in future pandemics. The decisions were taken during a two-day meeting convened in Geneva from 6-7 June.

"Vaccines are one of the most impactful and cost-effective health and development interventions available today," said Professor José Manuel Barroso, Chair of the Gavi Board. "As we look to 2030 and progress against the Sustainable Development Goals amidst climate change and other challenges, the message is clear: the world must continue to invest in the transformative impact of vaccines and their ability to save lives and ensure our collective security."

To set the scene for two days of discussions on Gavi's future direction, the Board first reviewed progress for the current strategic period, noting that the Alliance is largely on track across mission indicators despite the disruptions caused by the COVID-19 pandemic. Progress includes critical advances in the push to reach 86 million girls with vaccines against human papillomavirus (HPV), with five new country launches since September 2023, and the new malaria vaccination programme, where 22 country applications have been approved and deeper collaboration with the broader set of malaria stakeholders, including the Global Fund, is underway. While there has been a 12% reduction in the number of outbreaks requiring a response between 2022 and 2023, it continues to be an area of concern that this remains far above pre-pandemic averages, primarily driven by surges in cholera and measles outbreaks. 

The Board approved the Vaccine Alliance's strategy for the period 2026-2030, known as "Gavi 6.0". The 6.0 strategy will be the most ambitious in Gavi's history: seeking to protect more people, against more diseases, faster than ever before.

The new strategy will also make the Gavi model increasingly responsive to the evolving global context – from climate change to the increasing threat of outbreaks, antimicrobial resistance, and fragility and conflict – to continue meeting countries' and communities' needs.

"The decisions taken today reflect our full Alliance of stakeholders aligning around a clear goal: ensuring Gavi's model continues to best support the countries and communities who are our partners," said Dr Sania Nishtar, CEO of Gavi. "In a complex and changing world, today's decisions will help Gavi deliver systematic impact faster than ever before."